Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Eupraxia Pharmaceuticals in a research note issued on Thursday, July 24th. Cantor Fitzgerald analyst K. Kluska expects that the company will earn ($0.63) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $11.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals' current full-year earnings is ($0.67) per share. Cantor Fitzgerald also issued estimates for Eupraxia Pharmaceuticals' FY2026 earnings at ($0.64) EPS.
Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, June 16th. They issued a "speculative buy" rating for the company. HC Wainwright initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 26th. They set a "buy" rating and a $12.00 price objective on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $11.00.
Read Our Latest Report on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Stock Performance
NASDAQ EPRX traded up $0.02 on Monday, reaching $5.31. The company's stock had a trading volume of 4,275 shares, compared to its average volume of 13,838. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $6.20. The stock has a market cap of $190.77 million, a PE ratio of -6.98 and a beta of 1.55. The firm's 50 day moving average is $4.72 and its two-hundred day moving average is $3.93.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02).
Institutional Trading of Eupraxia Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new position in Eupraxia Pharmaceuticals in the fourth quarter worth approximately $37,000. Bank of Montreal Can increased its holdings in Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock worth $178,000 after buying an additional 7,500 shares during the last quarter. Millennium Management LLC acquired a new position in Eupraxia Pharmaceuticals in the fourth quarter worth approximately $31,000. Scotia Capital Inc. increased its holdings in Eupraxia Pharmaceuticals by 11.6% in the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock worth $5,072,000 after buying an additional 160,960 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock worth $1,125,000 after buying an additional 59,683 shares during the last quarter.
Eupraxia Pharmaceuticals Company Profile
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Further Reading
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access